Potent and selective CCR3 antagonist

PF-4136309 is a potent, Selective, and orally bioavailable CCR2 antagonist.

PF-4136309 is an orally available CCR2 antagonist with potential immunomodulating and antineoplastic activities.

C 021 2HCl is a potent CCR4 chemokine receptor antagonist.

ZK756326 is a full agonist of CCR8（Chemokine receptor 8） with an IC50 of 1.8 μM, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1.

BX471 HCl is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1) and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.

RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 98 nM and > 100 μM for inhibition of human recombinant CCR2b and CCR1 receptors respectively).

RS102895 HCl is a potent and specific CCR2 antagonist with binding IC50 of 360 nM, no significant inhibition on CCR1 (IC50 > 17 μM).

BX471 is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1) and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.

Cenicriviroc is an oral, dual CCR2/CCR5 antagonist, and displays potent anti-inflammatory and aninfective activity.

NSC 5844 is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic properties.

Cenicriviroc, also known as TAK-652 and TBR-652, is an experimental drug candidate for the treatment of HIV infection. It is being developed by Takeda Pharmaceutical and Tobira Therapeutics. Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell. Inhibition of CCR2 may have an anti-inflammatory effect.